INTRODUCTION
The continuing human immunodeficiency virus (HIV)/ AIDS epidemic highlights the urgent need for additional effective methods of prevention. More than 33 million people are living with HIV and the predominant mode of transmission is through heterosexual intercourse (UNAIDS/WHO, 2007) . While condoms are highly effective at preventing HIV infection, they require partner consent and are contraceptive, therefore they are not an available option for many women at risk of HIV infection (Shattock & Solomon, 2004) . Furthermore, women are biologically more susceptible to HIV and other sexually transmitted infections (European Study Group on Heterosexual Transmission of HIV, 1992) , and young women appear particularly vulnerable, accounting for 75 % of HIV infection in the 15-24 age group in sub-Saharan Africa (Quinn & Overbaugh, 2005) . Therefore new prevention methods that can be initiated by women are desperately needed. In the absence of a protective vaccine, renders the virus non-infectious. CV-N, an 11 kDa protein originally purified from the cyanobacterium Nostoc ellipsosporum, potently inactivates a wide spectrum of HIV-1 strains and primary isolates, as well as a number of other viruses including HIV-2, simian immunodeficiency virus, Ebola and hepatitis C virus (Barrientos & Gronenborn, 2005; Boyd et al., 1997; Helle et al., 2006) . The mechanism of action of CV-N involves multiple binding to high-mannose oligosaccharides predominantly in the C2-C4 region of the HIV-1 gp120 protein (Hu et al., 2007; Shenoy et al., 2001) . This binding then inhibits the conformational change required for virus-target cell attachment and subsequent fusion. Previous in vivo studies, with CV-N formulated as a gel, have shown promising efficacy when the compound was used topically as a rectal or vaginal microbicide in macaques challenged with the highly pathogenic SHIV89.6P virus (Tsai et al., 2003 (Tsai et al., , 2004 .
Thus potent antiviral activity, lack of toxicity, resistance to physico-chemical denaturation as well as the unusual high genetic barrier to resistance (Balzarini et al., 2006; Hu et al., 2007; Witvrouw et al., 2005) suggest that CV-N is a promising anti-HIV molecule for use as a topical microbicide (Boyd et al., 1997; Esser et al., 1999) .
Here we describe a detailed preclinical evaluation of CV-N, using both in vitro cell-based assays and an ex vivo tissue model. These studies expand and build on our early demonstration of compound efficacy in tissue and animal models (Tsai et al., 2004) . In this study, we have evaluated multiple aspects of CV-N activity including: the ability to block cell-free and cell-to-cell HIV-1 transmission; its activity in the presence of semen; efficacy in the presence of Candida albicans; and activity in human cervical explant cultures (Fletcher et al., 2005; Greenhead et al., 2000; Hu et al., 2004) . The potential mitogenic effects of CV-N have been assessed in peripheral blood mononuclear cell (PBMC) cultures, while the potential induction of inflammation has been assessed by measuring changes in production in a panel of 23 cytokines in both PBMC and cervical tissue explants. Determination of CV-N cytotoxicity. Prior to use in our experiments, the viability upon exposure to CV-N was determined in TZM-bl, PBMC and tissue explants by MTT reduction assay, as previously described (Greenhead et al., 2000; Mosmann, 1983 Cell-to-cell transmission assay. TZM-bl adherent indicator cells, which can be infected by both R5 and X4 HIV-1 and enable quantitative analysis of HIV-1 infection using either b-galactosidase or luciferase as reporter genes (Li et al., 2005; Wei et al., 2002) , were used in these experiments.
METHODS
TZM-bl cells were seeded at a concentration of 5610 4 per well in 96-well microplates. The following day, chronically infected PM1 cells (cell numbers corresponding to 100 TCID 50 ) were incubated with CV-N at different concentrations for 1 h at 37 uC. Medium was then removed from TZM-bl cells and infected PM1 cells, with or without compound, were added to wells in triplicate. After 1 h of incubation, wells were washed once to remove PM1 cells, and TZM-bl cells were incubated in complete DMEM for 24 h. The following day, cells were washed with PBS and lysed and luciferase expression was assessed after addition of substrate (Luciferase Assay System, Promega) as previously described (Wei et al., 2002) .
Proliferation assay. PBMCs were seeded at a concentration of 2610 5 cells per well in triplicate and incubated with CV-N at different concentrations for either 2 h or 3 days. Positive control cells were incubated with 2 mg PHA ml 21 . After 3 days the cultures were pulsed for 16-18 h with 1 mCi (37 kBq) [ 3 H]thymidine per well and then harvested as described above. Cellular DNA was captured on a filter membrane and dried and incorporated radioactivity was measured by scintillation counter (Beckman). The stimulation index was calculated by dividing the mean c.p.m. value of stimulated samples by the mean c.p.m. of unstimulated ones.
Inhibition of infection in the presence of semen. Semen was obtained from five different donors with written consent (according to the local research ethics committee) and pooled before use. An aliquot of semen was heat-inactivated (HI) for 30 min at 56 uC. Virus, either HIV-1 BaL or HIV-1 RF was then incubated with fresh semen, used at a concentration of 25 %, HI semen or media for 1 h at 37 uC as previously described (Bouhlal et al., 2002) . TZM-bl were seeded as described above and exposed to various concentrations of CV-N for 1 h prior to infection. Virus, in the presence or absence of semen and HI semen, was then added to TZM-bl cells, in the presence of CV-N, for 24 h. The final concentration of semen was 12.5 % (v/v), a concentration determined by MTT assay to be non-toxic for TZMbl cells CC 50 [50 % cellular cytotoxicity (of the pooled semen corresponding to 57 %)], this concentration of semen did not affect any of the assay parameters and did not cause any detectable enhancement of infection. The following day luciferase expression was measured as described above.
Inhibition of infection in the presence of C. albicans. TZM-bl cells were exposed to various concentrations of CV-N for 1 h prior to infection in the presence of different dilutions of HI C. albicans, (strain SC5314, kindly provided by Professor C. Kelly, King's College, London, UK). Then either HIV-1 BaL or HIV-1 RF (1006 TCID 50 ) was added to the cell cultures and incubated overnight. The following day luciferase was measured as described above.
Purification of HIV-1 particles and biosensor binding assay.
Viral stocks HIV-1 BaL and HIV-1 RF were inactivated with 1 mM aldrithiol-2 (AT-2) for 1 h at 37 uC, clarified, layered on top of a 20 % sucrose gradient and centrifuged at 100 000 g for 18 h at 4 uC, as previously described (Segura et al., 2006) . Viral pellets were resuspended and subsequently incubated with CD45-conjugated microbeads (Miltenyi Biotec) for 3 h, after which microparticles, rich in CD45, were magnetically removed, leaving purified functional viral particles as previously described (Esser et al., 2001; Trubey et al., 2003) . CD45-depleted viral particles were then repelleted and subsequently resuspended in degassed HEPES buffer for functional binding experiments.
In order to assess the binding of CV-N to HIV-1, an acoustic biosensor was used. The automated four channel RAP-ID platform (Akubio) was used in this study according to a protocol described previously . CV-N was first covalently bound to a quartz crystal chip, and then purified viral particles were allowed to flow over the surface. The binding of CV-N to free virus causes a change in mass of the flowing cells, which is interpreted as a difference in resonant frequency. In this way it was possible to determine kinetics and interaction half-life between the virus particles and the compound. CV-N was titrated on this platform for binding to HIV-1 BaL and HIV-1 RF , as well as a CV-Nresistant HIV-1 isolate (Hu et al., 2007) . PHA was immobilized separately and used as a non-specific control lectin.
Culture and infection of human genital tissue explants. Cervical explant culture was performed as previously described (Fletcher et al., 2005; Greenhead et al., 2000; Hu et al., 2004) . Tissue was obtained from women undergoing planned therapeutic hysterectomy at St George's and Kingston Hospitals (London, UK) with written consent (according to the local research ethics committee). Cervical tissue, including both epithelium and stroma, was cut into 3 mm 3 explants and cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum, 100 U penicillin ml
21
, 100 mg streptomycin ml 21 and 2 mM L-glutamine.
Explants were pretreated for 2 h with CV-N at different concentrations before exposure to HIV-1 BaL (5610 4 TCID 50 ) for 2 h at 37 uC. Subsequently, explants were washed four times with PBS and cultured overnight in 96-well microplates without readdition of the compound. The following day, explants were transferred to a new microplate and cultured in medium only for 11 days, with supernatant harvests every 3 days.
Migratory cells, present in the overnight culture plate, were washed with PBS and co-cultured with 4610 4 PM1 cells, in order to assess virus transfer. Supernatants were harvested every 3 days. HIV-1 infection was determined by p24 ELISA in both culture supernatants. The high-sensitivity INNOTEST p24 ELISA kit (Innogenetics Group; lower detection limit 5 pg ml 21 ) was used for explant supernatants, while the ELISA from NCI was used for the migratory-cell culture, where higher levels of p24 are produced.
Cytokine detection by multiplex bead immunoassay. Tissue explants or PBMC were exposed to different concentrations of CV-N. Explants were exposed to compound for 2 h, then washed and cultured overnight with medium only. Supernatants were collected both after 2 h exposure and after overnight incubation. PBMCs were exposed to CV-N for either 2 h or 3 days, and cytokine release was assayed after 3 days of culture, in parallel with the proliferation assay.
Culture supernatants were simultaneously assessed for the presence of the following cytokines: granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), beta interferon (IFN-b), IFN-c, interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-12, IL-15, IL-16, IP-10, monocyte chemoattractant protein (MCP)-1, MCP-2, monokine induced by IFN-c (MIG), macrophage-inflammatory protein (MIP)-1a, MIP-1b, RANTES, stromal cell-derived factor (SDF)-1b, transforming growth factor (TGF)-b and tumour necrosis factor (TNF)-a. In this assay, beads (Bio-Rad) were dyed with different concentrations of fluorophores in order to create distinct sets. Each set was then coated with an antibody specific for one of the analytes (R&D Systems) and the captured analyte was detected with a byotinylated antibody (R&D Systems) and following incubation with streptavidin-phycoerithrin (S-PE; Sigma). Plates were read using the Luminex 100 system (Luminex) and data were analysed using the Bioplex Manager version 4.0 software (Bio-Rad). Lower detection limits for this assay were 5.3 pg ml 21 (G-CSF, IFN-b, IFN-c, IL-1a, IL-1b, IL-2, IL-4, IL-16, IP-10, MCP-2, MIG, MIP-1a, MIP-1b, RANTES, SDF-1b and TNF-a), 2.6 pg ml 21 (IL-12, IL-15 and TGF-b), 5.6 pg ml 21 (MCP-1, IL-6 and IL-8) and 2.8 pg ml 21 (GM-CSF).
RESULTS

Antiviral activity of CV-N against laboratory and primary isolates
To confirm the antiviral activity of CV-N used in these studies, it was first tested against three clade B HIV-1 laboratory strains, as examples of R5 and X4 viruses. (Balzarini et al., 2006; Boyd et al., 1997) .
Analysis of the binding kinetics of CV-N to HIV-1
To further understand differences in CV-N activity against the different isolates tested, the kinetics of CV-N binding to viral particles was examined using an acoustic biosensor V. Buffa and others (Rapid 4; Akubio). In this system CV-N was first immobilized to the surface of a quartz crystal chip, AT-2 inactivated viral particles were then flowed over the surface. The variation in resonant frequency observed, a result of HIV-1 binding to the compound, allows determination of the kinetic parameters of the interaction. In these experiments HIV-1 BaL and HIV-1 RF were studied, along with a CV-N-resistant isolate of HIV-1 IIIB generated in vitro (Hu et al., 2007) . HIV-1 RF demonstrated potent binding to CV-N (Fig. 1b) (Fig. 1a) (Fig. 1c) and the K d observed was the highest of the viruses examined (18 mM), with a binding affinity that was 8 % of that for HIV-1 RF and 9 % of that for HIV-1 BaL . PHA was tested as a non-specific control; this lectin did not show any appreciable binding of any of the viruses tested (Fig. 1d , e and f).
Inhibition of cell-associated HIV-1 transmission by CV-N
Having determined the activity of CV-N against cell-free virus, its activity against cell-associated HIV-1 was evaluated using the same laboratory isolates. Chronically infected PM1 T cells were incubated with TZM-bl cells for 1 h, in the presence or absence of CV-N. After overnight culture, inhibition of infection was measured by luciferase assay. CV-N demonstrated potent activity against cell-associated infection with each of the three evaluated viruses, HIV-1 BaL , HIV-1 RF and HIV-1 IIIB , with IC 50 values of 0.046, 0.004 and 0.025 mM, respectively (Fig. 2) .
CV-N activity in the presence of semen
Since semen represents a natural vehicle for HIV-1 transmission, preservation of activity in its presence is an important parameter for microbicide candidate selection. Inhibition of HIV-1 BaL and HIV-1 RF by CV-N was tested using TZM-bl cells, in the presence or absence of whole semen [used at final concentration of 12.5 % (v/v)]. HI of semen was performed in order to assess if any of the complement components had an effect on CV-N efficacy, since it is known that virus opsonization can enhance virus infectivity (Bouhlal et al., 2002) .
Dose response curves for activity against HIV-1 BaL suggest that semen had some effect on CV-N activity with the IC 50 increasing from 0.005 mM in the absence of semen to 0.036 mM in the presence of semen (Fig. 3a) . This effect appeared to be complement-independent, as the dose 
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response curves for semen and HI-semen show a similar trend, and the IC 50 values are similar (0.036 and 0.029 mM, respectively). Similarly, for HIV-1 RF there was an increase in the IC 50 value in the presence of semen (from 0.001 to 0.01 mM), whilst no significant differences were observed between semen and HI-semen (IC 50 values of 0.01 and 0.025 mM) with ratios to the control (without semen) of 10 and 8.3, respectively (Fig. 3b) . The maximal 10-fold increase in IC 50 values in the presence of semen observed in this study is markedly lower than that reported for other microbicide candidates (Neurath et al., 2006; Patel et al., 2007) .
CV-N activity in the presence of C. albicans
The ability of CV-N to prevent HIV-1 infection was determined in the presence of C. albicans, a common genital infection that expresses high levels of mannan residues, in different linkages and that can be recognized by a number of carbohydrate-binding lectins (Lillegard et al., 2006) . Here target cells were pretreated with CV-N in the presence of Candida, at different dilutions, then exposed to either HIV-1 BaL or HIV-1 RF . The anti-HIV activity of CV-N was not impaired by the presence of Candida, at any of the concentrations tested and for both viruses. The IC 50 values were very similar [0.005 mM for HIV-1 BaL (Fig. 4a ) and 0.001 mM for HIV-1 RF (Fig. 4b)] , with no significant shifts in the dose response curves.
Inhibition of HIV-1 infection in human cervical tissue and blockade of virus propagation by migratory cells
The ability of CV-N to prevent infection of the female genital tract was examined using ectocervical explants cultured in a non-polarized manner (Fletcher et al., 2005; Greenhead et al., 2000; Hu et al., 2004) . Since R5 viruses predominate in the early stages of HIV-1 infection (Zhu et al., 1993) we selected the isolate HIV-1 BaL for these experiments. CV-N was previously tested for its potential toxicity on tissue explants by MTT viability assay as described (CC 50 .0.45 mM, data not shown). Explants were pre-treated with a dilution series of CV-N for 2 h then exposed to HIV-1 BaL (2 h) before washing in order to remove unbound virus and CV-N. Infection was monitored by p24 release following 11 days in culture. CV-N prevented infection of cervical tissue explants, in a dose-dependent fashion, with an IC 50 of 0.02 mM (Fig.  5a ). Moreover, a 1 mM dose of CV-N was sufficient to provide 90 % protection against HIV-1 BaL infection.
We have previously shown spontaneous migration of CD4 + dendritic cells (DC) from cervical explant tissue during overnight culture, a population of cells able to bind virus via mannose C-type lectin receptors (MCLR) and/or CD4 (Hu et al., 2004) . Migratory cells were harvested from explant cultures (exposed to compound and virus as described above) following overnight culture, washed to eliminate cell-free virus, and cocultured with permissive PM1 T cells. CV-N inhibited the transfer of virus from migratory cells as well. The concentration of 1 mM provided a maximum of 70 % protection against viral dissemination after 7 days of cell culture (Fig. 5b ).
Analysis of potential mitogenicity
As CV-N is a carbohydrate-binding agent (CBA), it was important to determine whether it could stimulate T-cell proliferation. The mitogenic properties of CV-N were assayed in PBMCs, after 3 days of culture by measurement of [ 3 H]thymidine incorporation. The compound was previously tested on PBMCs for its cytotoxic effects by a MTT dye reduction assay (CC 50 value 1.63 mM, data not shown) and used at non-toxic concentrations. As previously demonstrated (Balzarini et al., 2006) , CV-N has some mitogenic activity after 3 days of incubation with PBMCs, with a maximal stimulation index (SI) of 5 (Fig.  6a) . We also tested proliferation after a 2 h exposure to the compound, followed by 3 days of culture, and the rate of proliferation was drastically reduced under these conditions with a maximal SI of 4 observed at the highest concentration tested (1.8 mM) . For the other concentrations tested the SI was always below 2. The positive control PHA, used at a concentration corresponding to one tenth of the highest point tested for CV-N, showed SI values above 10 (Fig. 6a) .
In parallel with the [ 3 H]thymidine incorporation assay, culture supernatants were also tested for the presence of cytokines by Luminex assay. For cultures exposed to CV-N for 2 h no variation in the expression profile of 23 cytokines was detected, while those exposed to CV-N for 3 days demonstrated statistically significant (P,0.05) increases in the amounts of SDF-1b, IL-4 and IFN-c released (Fig. 6b) . . Proliferative effects and cytokine expression upon exposure to CV-N. Proliferation was assayed in PBMCs after 3 days of culture. Cells were exposed to CV-N at different concentrations for 2 h or 3 days (a). The SI was calculated by dividing the mean c.p.m. value of stimulated samples by the mean c.p.m. of unstimulated ones. Supernatants were then tested for cytokine release by Luminex and a significant increase (*, P,0.05) in the production of IFN-c, IL-4 and SDF-1b was observed at the highest concentrations tested (b). Data represent the mean±SEM of three independent experiments; each condition was tested in triplicate.
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Effects of CV-N on cytokine expression in cervical tissue
In order to determine whether exposure of cervical tissue to CV-N would induce an inflammatory response, culture supernatants were also tested to determine any modulation of the secreted cytokine profile. Previous work validated this detection method and showed that compounds such as PRO2000 and dextran sulphate can induce significant increases of cytokines in cervical explants (Fletcher et al., 2006) .
In these experiments explants were exposed to CV-N for 2 h then washed and cultured overnight. Supernatants were collected after 24 h and analysed by multiplex bead immunoassay. Untreated explants produced detectable levels of a wide range of cytokines (Table 2) . Treatment with CV-N did not alter the production of the majority of the cytokines, and whilst there was a slight increase in G-CSF, IL-8 and IP-10 release, this did not reach statistical significance.
DISCUSSION
In this study we have performed a detailed preclinical evaluation of CV-N as a potential HIV-1 microbicide. The activity of CV-N against a broad range of primary isolates from different clades confirms previous studies and validates the activity of the CV-N used in this study (Balzarini et al., 2006; Boyd et al., 1997) . Interestingly, activity seemed higher against primary strains than against laboratory isolates, a positive trait for a potential microbicide candidate. The ability of this candidate to inactivate a wide spectrum of laboratory strains and clinical primary isolates underlines the conserved nature of CV-N binding sites on gp120 and the high genetic barrier of this compound, already demonstrated with drug-resistance selection studies (Balzarini et al., 2006; Hu et al., 2007; Witvrouw et al., 2005) .
In order to further understand the differences in IC 50 values observed in TZM-bl for HIV-1 BaL and HIV-1 RF (0.005 and 0.001 mM, respectively), CV-N was tested for binding to these viruses with an acoustic biosensor (Akubio) that provides information about the kinetics of binding. HIV-1 RF bound to CV-N more rapidly and dissociated more slowly than HIV-1 BaL , with binding percentages of 100 and 85 %, respectively. A CV-Nresistant virus (Hu et al., 2007) was used as a control and showed only 8-9 % of the binding to HIV-1 RF and HIV-1 BaL . Furthermore, the control lectin PHA failed to bind virus. These results confirmed that differences in activity are related to CV-N affinity and may reflect differences in the amount of potential glycosylation sites between these two viruses (data not shown).
Semen is a natural vehicle for male-to-female and male-tomale transmission of HIV-1 and is generally not included in preclinical challenge studies performed in monkeys. However, previous studies (Neurath et al., 2006; Patel et al., 2007) have demonstrated that the activity of some compounds can be markedly reduced in the presence of semen, and that this is an important consideration when selecting candidates for microbicide development. In this study, inclusion of semen had a modest effect on its antiviral activity (Fig. 3) , with a maximum tenfold increase in the IC 50 value. This reduction in efficacy is far less than that seen for compounds already in phase III clinical trials and may be insignificant when considering the high concentration of CV-N (1 and 2 % gels, corresponding to 0.9 and 1.8 mM) used to prevent vaginal transmission in the macaque challenge model (Tsai et al., 2003) . It has yet to be determined whether the reduction in activity reflects masking of high-mannose residues on the virus by seminal plasma components or binding of CV-N to the components themselves (Sabatté et al., 2007) .
The antiviral activity of CV-N was also evaluated in the presence of C. albicans, a yeast that displays on its cell-wall several mannose residues that can be recognized by lectins (Lillegard et al., 2006) . This is a common cause of genital infections in women, particularly in immunocompromised individuals (Dupont et al., 1992; Fichtenbaum & Powderly 1998 ). Our studies demonstrate that CV-N retains potent activity against HIV-1 in the presence of C. albicans without an increase in the IC 50 values (Fig. 4) . While we cannot exclude the possibility that other C. species or isolates might bind CV-N, these data suggest it is unlikely to be common to the species as a whole.
As well as inhibiting transmission of cell-free HIV-1, CV-N was able to block cell-associated virus, regardless of the R5 or X4 tropism of the strains examined (Fig. 2) , although in the main this required a tenfold increase in concentration.
In this respect, its activity was more potent than a range of neutralizing monoclonal antibodies currently being evaluated in this model (data not shown).
Results obtained in our ex vivo tissue explant model demonstrate that CV-N was able to inhibit HIV-1 BaL infection in cervical explants, with an IC 90 of 1 mM. Moreover, this concentration inhibited 70 % of virus dissemination by dendritic cells that spontaneously migrate out of the tissue explants. These data are in keeping with previous observations of activity against cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-mediated transmission in cellular models Turville et al., 2005) , suggesting that CV-N may be active against in cis and in trans cellmediated infection. The higher IC 50 value (0.36 mM) observed in our migratory cell model (compared with previous studies) might be due to differences between experimental protocols, such as the shorter time of exposure to CV-N used here and the lack of readdition of the compound after infection . The 2 h exposure time chosen for this study takes into consideration that a woman would most probably apply a microbicide based on CV-N in a coitally dependent fashion and that the concentration would rapidly diminish following intercourse through associated dilution due to vaginal fluid, ejaculated semen and probable post-coital cleansing by the woman. It is hard to anticipate the level of compound that would be retained for a prolonged period after intercourse; however, our observation that a 2 h exposure to CV-N can inhibit infection is encouraging even if levels can be maintained for a prolonged period following intercourse through appropriate formulation.
While compound activity under physiological conditions is a critical parameter for microbicide selection, compound safety is equally important. This has been thrown into sharp relief by recent safety concerns over the prematurely halted phase III trial of cellulose sulphate (Honey, 2007) and previous studies of nonoxynol-9 products (Van Damme et al., 2002) . Safety is of paramount importance for microbicides as they will be used by at risk populations and possibly several times a day. In this study no tissue toxicity was observed with the highest concentrations of CV-N tested (0.45 mM). However, in common with other lectins, a previous study (Balzarini et al., 2006) indicated that CV-N has some mitogenic properties for PBMCs, raising some safety concerns over its in vivo use. In this study, 3 days exposure of PBMC to CV-N did induce low levels of T-cell proliferation, with a maximum stimulation index of 5.4 at 0.36 mM and increased levels of SDF-1b, IL-4 and IFN-c release (Fig. 6b) . However, proliferation was greatly reduced when exposure to CV-N was reduced to 2 h followed by 3 days in culture (Fig. 6a) , and no significant alteration in the normal pattern of cytokine expression was observed at 24 h. In agreement with these findings, analysis of cytokine production by cervical tissue explants exposed to CV-N for 2 h demonstrated no significant alterations of the normal profile of cytokine expression. It is unclear whether the low mitogenic activity seen with PBMC cultures exposed to CV-N for 3 days would be representative of responses to topically applied CV-N in vivo. Indeed, no adverse effects were seen in macaques following vaginal or rectal application of 5 mg formulated in HMC gel (Tsai et al., 2003) . Nevertheless, repeat application studies would be required to exclude any chronic inflammatory potential.
In conclusion, CV-N demonstrates potent cross-clade activity, retains its activity in the presence of semen and C. albicans and is able to block infection in cellular and ex vivo human genital explant models. While potential mitogenic properties raise some safety concerns, their in vivo relevance could be assessed in non-human-primate studies. Furthermore, discovery of additional carbohydrate-binding agent candidates, such as Griffithsin, that do not show any mitogenic activity in PBMCs (data not shown) adds weight to the concept that targeting HIV glycoproteins will provide an important strategy in preventing HIV transmission.
